literature

HIV mutation literature information.

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.

PMID: 32675772 2020 Journal of acquired immune deficiency syndromes (1999)

Abstract: Participants with screening HIV-1 RNA <50 copies/mL for >=6 months; no prior virologic failure; and no documented resistance-associated major protease inhibitor, integrase inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), or non-NRTI mutations or integrase resistance-associated substitution R263K were randomly assigned 1:1 to switch to once-daily dolutegravir 50 mg plus rilpivirine 25 mg on day 1 (early-switch group) or to continue their current antiretroviral regimen and, if virologically suppressed at week 48, switch to dolutegravir plus rilpivirine at week 52 (late-switch group) until week 148.

Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.

PMID: 30951600 2020 Journal of the Pediatric Infectious Diseases Society

Abstract: HIV-1 genotypic drug resistance testing was available at time of failure from 6 participants; 1 had evolution in integrase resistance with E138T, S147G, and R263K mutations at week 192 and phenotypic dolutegravir resistance of a 5.1-fold change.

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.

PMID: 31330378 2020 Journal of global antimicrobial resistance

Abstract: Before INSTI treatment one patient harboured the major INSTI-RM R263K and three patients the accessory INSTI-RMs T97A.

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.

PMID: 31617907 2020 The Journal of antimicrobial chemotherapy

Abstract: Among the 29 relatively common INSTI-selected mutations, 24 emerged as candidates for inclusion on a list of INSTI surveillance drug-resistance mutations: T66A/I/K, E92G/Q, G118R, F121Y, E138A/K/T, G140A/C/S, Y143C/H/R/S, S147G, Q148H/R/K, N155H, S230R and R263K.

Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.

PMID: 31982483 2020 Antiviral research

Abstract: After several weeks, virological failure was confirmed with 4.01 HIV RNA Log copies/mL and R263K and M184V resistance mutations were detected.

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Result: The DTG resistance associated mutation R263K was not found.

Discussion: The E157Q substitution (found in subject 13) is a natural polymorphism described as a compensatory mutation for R263K-mediated DTG resistance and after RAL exposure.

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

PMID: 32105319 2020 The Journal of antimicrobial chemotherapy

Abstract: Two had Q148K minority variants and two had R263K (one of whom also had L74I).

Result: Two had Q148K and two had R263K minority variants (one of whom also had L74I).

Discussion: One individual out of 115 had both L74I and the signature dolutegravir mutation R263K detected by next-generation sequencing, though R263K was a minority variant.

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.

PMID: 33228206 2020 Viruses

Result: This resistance test newly revealed the E138K, Q148R, and R263K INSTI mutations at frequencies of 100% by means of next-generation sequencing (NGS), causing high-level resistance to RAL, EVG, DTG, and BIC.

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.

PMID: 32379830 2020 PloS one

Table: R263K

Occurrence of the S230R integrase strand inhibitor mutation in a treatment-naive individual case report.

PMID: 32629687 2020 Medicine

Discussion: Common INSTI RAMS include R263K, Q148H/R/K, G118R, G140A/S/C, E138A/K/T, N155H, and Y143C/R.

Discussion: These results demonstrated that the S230R substitution caused similar effects on viral replicative capacity as R263K, which is known to be selected in vitro by EVG, DTG, and BIC causing viral resistance on an incompletely suppressive DTG containing regimen.

Browser Board

Co-occurred Entities

Filtrator